PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 7, 2026Multiple Sclerosis Journal0 citations

Cardiovascular comorbidities are associated with cross-sectional and longitudinal measures of multiple sclerosis fatigue

View Full Paper
MGMahsa GhajarzadehEMEllen M MowryKFKathryn C Fitzgerald

Key Points

  • The research aims to determine how cardiovascular comorbidities affect fatigue levels in individuals with multiple sclerosis over time.
  • Analyzed prospective data from the MS PATHS database across 10 centers.
  • Measured fatigue using Neuro-QoL Fatigue T-scores.
  • Defined cardiovascular comorbidity as a composite and count of conditions.
  • Used multivariable regression for modeling associations.
  • 49% of participants had no cardiovascular comorbidities, while 3% had three.
  • Higher fatigue was associated with any comorbidity, particularly in cross-sectional models.
  • Longitudinal analyses indicated larger effect sizes with a consistent relationship over time.

Abstract

Background: Fatigue is common in multiple sclerosis and may be influenced by cardiovascular comorbidities. Objective: To test whether cardiovascular comorbidity burden relates to fatigue at baseline and over time, and to assess dose response. Methods: We analyzed prospectively collected data from MS PATHS across 10 centers. Fatigue was measured with Neuro-QoL Fatigue T -scores. Cardiovascular comorbidity was defined as a composite (any vs none) and as a count of hypertension, diabetes, and dyslipidemia. Cross-sectional associations and longitudinal trajectories were modeled using multivariable regression. Extended models also included depression, anxiety, and sleep disturbance. Results: Among 5507 participants, 49% had no cardiovascular comorbidity, 32% had one, 16% had two, and 3% had three. In minimally adjusted cross‑sectional models, any comorbidity was associated with higher fatigue (beta = 0.85; 95% CI, 0.18 to 1.53), with attenuation after adjustment for depression, anxiety, and sleep (beta = 0.20; 95% CI, −0.09 to 0.49). A graded dose response was evident across 0–3 conditions. In longitudinal analyses, effect sizes were larger and remained positive after adjustment (Any vs None: beta = 1.06 in minimal models; beta = 0.39 after adjustment), consistent with a greater comorbidity burden associated with higher fatigue over time. Conclusions: Cardiovascular comorbidity burden is associated with greater fatigue, with a dose response over time.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ghajarzadeh et al. (2026) studied this question.

synapsesocial.com/papers/69d4a00eb33cc4c35a228694https://doi.org/10.1177/13524585261438014
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies2011 · 12,307 citations
  2. 2Validating Neuro-QoL short forms and targeted scales with people who have multiple sclerosis2015 · 108 citations
  3. 3Fatigue in Multiple Sclerosis: Mechanisms, Evaluation, and Treatment2010 · 414 citations
  4. 4Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis2010 · 481 citations
  5. 52017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary2017 · 934 citations